Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGG A MILLER

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1902820756
CMS profile
1214613
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$621,860.00

290 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $470,385.00 257
PFIZER INC. $148,650.00 26
Gilead Sciences, Inc. $1,825.00 6
Progenics Pharmaceuticals, Inc. $1,000.00 1

Page 4 of 6; records 151–200 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGG A MILLER

NPI 1902820756 · CMS profile ID 1214613

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902820756?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGG A MILLER, NPI 1902820756, CMS profile ID 1214613. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902820756?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GREGG A MILLER, NPI 1902820756, CMS profile ID 1214613. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902820756?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GREGG A MILLER, NPI 1902820756, CMS profile ID 1214613, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1902820756?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

290 matching records · $621,860.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 290 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 290.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $122.5007/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848404699 CMS
Merck Sharp & Dohme LLC $1,170.0007/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848558259 CMS
Merck Sharp & Dohme LLC $5,520.0007/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848677523 CMS
Merck Sharp & Dohme Corporation $180.0006/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848404159 CMS
Merck Sharp & Dohme Corporation $240.0006/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848557977 CMS
Merck Sharp & Dohme LLC $350.0006/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848552887 CMS
Merck Sharp & Dohme Corporation $180.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848403047 CMS
Merck Sharp & Dohme Corporation $540.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848404993 CMS
Merck Sharp & Dohme Corporation $60.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848405369 CMS
Merck Sharp & Dohme Corporation $3,000.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848405641 CMS
Merck Sharp & Dohme Corporation $990.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848510353 CMS
Merck Sharp & Dohme Corporation $360.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848510481 CMS
Merck Sharp & Dohme Corporation $1,260.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848529179 CMS
Merck Sharp & Dohme Corporation $422.5006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848529185 CMS
Merck Sharp & Dohme Corporation $41,520.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848551023 CMS
Merck Sharp & Dohme Corporation $2,340.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848598819 CMS
Merck Sharp & Dohme Corporation $540.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848664901 CMS
Merck Sharp & Dohme Corporation $600.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848679253 CMS
Merck Sharp & Dohme Corporation $360.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848718573 CMS
Merck Sharp & Dohme LLC $120.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848405371 CMS
Merck Sharp & Dohme LLC $1,800.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848664905 CMS
Merck Sharp & Dohme LLC $422.5006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848729901 CMS
Merck Sharp & Dohme Corporation $680.0006/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848404983 CMS
Merck Sharp & Dohme Corporation $245.0006/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848404985 CMS
Merck Sharp & Dohme Corporation $660.0006/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848488697 CMS
PFIZER INC. $3,400.0006/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832831119 CMS
PFIZER INC. $14,200.0006/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833191781 CMS
Merck Sharp & Dohme Corporation $3,380.0005/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848463567 CMS
Merck Sharp & Dohme Corporation $360.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848404991 CMS
Merck Sharp & Dohme Corporation $12,212.5005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848405373 CMS
Merck Sharp & Dohme Corporation $3,420.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848405781 CMS
Merck Sharp & Dohme Corporation $1,140.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848449997 CMS
Merck Sharp & Dohme Corporation $120.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848463709 CMS
Merck Sharp & Dohme Corporation $230.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848463713 CMS
Merck Sharp & Dohme Corporation $302.5005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848463715 CMS
Merck Sharp & Dohme Corporation $60.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848472873 CMS
Merck Sharp & Dohme Corporation $11,942.5005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848515151 CMS
Merck Sharp & Dohme Corporation $1,565.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848598817 CMS
Merck Sharp & Dohme Corporation $4,800.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848635847 CMS
Merck Sharp & Dohme Corporation $1,740.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848658847 CMS
Merck Sharp & Dohme Corporation $1,560.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848687681 CMS
Merck Sharp & Dohme Corporation $360.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848706229 CMS
Merck Sharp & Dohme Corporation $62.5005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848730049 CMS
Merck Sharp & Dohme LLC $4,200.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848551025 CMS
Merck Sharp & Dohme LLC $300.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848579863 CMS
Merck Sharp & Dohme Corporation $170.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848529045 CMS
Merck Sharp & Dohme Corporation $4,765.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848637713 CMS
Merck Sharp & Dohme Corporation $355.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848658725 CMS
Merck Sharp & Dohme Corporation $545.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848658727 CMS
PFIZER INC. $3,130.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832831099 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $444,739.20 169
PY2020 $595,230.00 243
PY2021 $621,860.00 290
PY2022 $64,420.00 12
PY2023 $35,140.00 11
PY2024 $30,487.50 19
PY2025 $52.29 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $109,709.00 22
PY2025 Principal investigator $356,635.00 23
PY2024 Recipient $27,595.00 5
PY2024 Principal investigator $264,512.51 20
PY2023 Recipient $105,775.00 6
PY2023 Principal investigator $869,247.57 21
PY2022 Recipient $300.00 2
PY2022 Principal investigator $309,616.28 15
PY2021 Principal investigator $260,008.17 24
PY2020 Principal investigator $174,709.37 23
PY2019 Recipient $6,280.00 1
PY2019 Principal investigator $159,155.89 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharma AG $540.00 12/23/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248109001
Principal investigator 1 Novartis Pharma AG $180.00 11/18/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108991
Principal investigator 1 Novartis Pharma AG $1,015.00 10/21/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108983
Recipient E.R. Squibb & Sons, L.L.C. $5,512.00 10/03/2025 Covered Recipient Physician A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1236002109
Recipient E.R. Squibb & Sons, L.L.C. $12,240.00 10/03/2025 Covered Recipient Physician A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1236002117
Recipient E.R. Squibb & Sons, L.L.C. $150.00 10/03/2025 Covered Recipient Physician A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1236002119
Principal investigator 1 Novartis Pharma AG $835.00 09/16/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108987
Principal investigator 1 Novartis Pharma AG $705.00 09/02/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108999
Recipient E.R. Squibb & Sons, L.L.C. $775.00 08/08/2025 Covered Recipient Physician A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer No dispute reported 06/30/2026 1236002097
Recipient E.R. Squibb & Sons, L.L.C. $9,150.00 08/08/2025 Covered Recipient Physician A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 1236002115
Principal investigator 1 AstraZeneca UK Limited $9,915.00 08/07/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
a phase third,randomized,double blind,placebo controlled,multi centre,global study of volrustomig in women with high risk locally advanced cervical cancer who have not progressed following platinum based,concurrent chemoradiation therapy evolve cervical No dispute reported 06/30/2026 1185541810
Recipient GlaxoSmithKline, LLC. $240.00 08/07/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136059
Principal investigator 1 Novartis Pharma AG $120.00 08/05/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CTL019E2301 No dispute reported 06/30/2026 1248108975
Principal investigator 1 Novartis Pharma AG $1,880.00 07/15/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108995
Recipient GlaxoSmithKline, LLC. $420.00 07/08/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136054
Recipient E.R. Squibb & Sons, L.L.C. $7,930.00 07/03/2025 Covered Recipient Physician A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer No dispute reported 06/30/2026 1236002103
Recipient E.R. Squibb & Sons, L.L.C. $329.00 07/03/2025 Covered Recipient Physician A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigators Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy No dispute reported 06/30/2026 1236002113
Principal investigator 1 Novartis Pharma AG $1,580.00 07/01/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108993
Recipient GlaxoSmithKline, LLC. $3,660.00 06/19/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136098
Principal investigator 1 AstraZeneca UK Limited $3,020.00 05/27/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185541804
Principal investigator 1 Novartis Pharma AG $1,555.00 05/27/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108989
Principal investigator 1 AstraZeneca UK Limited $2,690.00 05/15/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185541812
Principal investigator 1 AstraZeneca UK Limited $130.00 05/13/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185541806
Principal investigator 1 Novartis Pharma AG $120.00 05/13/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CTL019E2301 No dispute reported 06/30/2026 1248108981
Recipient E.R. Squibb & Sons, L.L.C. $170.00 05/05/2025 Covered Recipient Physician A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer No dispute reported 06/30/2026 1236002107
Recipient GlaxoSmithKline, LLC. $6,540.00 04/10/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136075
Recipient E.R. Squibb & Sons, L.L.C. $75.00 04/03/2025 Covered Recipient Physician A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1236002099
Recipient E.R. Squibb & Sons, L.L.C. $4,052.00 04/03/2025 Covered Recipient Physician A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigators Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer No dispute reported 06/30/2026 1236002105
Recipient GlaxoSmithKline, LLC. $1,860.00 04/03/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136080
Principal investigator 1 Novartis Pharma AG $205.00 03/27/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248108997
Principal investigator 1 Novartis Pharma AG $240.00 03/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CTL019E2301 No dispute reported 06/30/2026 1248108979
Recipient Ipsen Innovation $75.00 03/06/2025 Covered Recipient Physician A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302761
Principal investigator 1 Novartis Pharma AG $115.00 02/25/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
CTL019E2301 No dispute reported 06/30/2026 1248109003
Principal investigator 1 Novartis Pharma AG $240.00 02/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CTL019E2301 No dispute reported 06/30/2026 1248108977
Recipient E.R. Squibb & Sons, L.L.C. $48,716.00 02/06/2025 Covered Recipient Physician A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1236002093
Recipient GlaxoSmithKline, LLC. $720.00 02/06/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136065
Principal investigator 1 AstraZeneca UK Limited $18,270.00 01/21/2025 Non-covered Recipient Entity
REMEDIUM IMAGING LLC
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1185541808
Principal investigator 1 Amgen Inc. $18,250.00 01/14/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1246641835
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $176,772.50 01/14/2025 Non-covered Recipient Entity
GI Reviewers
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy No dispute reported 06/30/2026 1235997097
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $102,887.50 01/09/2025 Non-covered Recipient Entity
GI Reviewers
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma No dispute reported 06/30/2026 1235997099
Recipient GlaxoSmithKline, LLC. $3,780.00 01/09/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192136086
Principal investigator 1 AstraZeneca UK Limited $15,370.00 01/07/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185541800
Recipient E.R. Squibb & Sons, L.L.C. $1,440.00 01/03/2025 Covered Recipient Physician A Phase 1 Firstinhuman Study of BMS986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors No dispute reported 06/30/2026 1236002095
Recipient E.R. Squibb & Sons, L.L.C. $605.00 01/03/2025 Covered Recipient Physician A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer No dispute reported 06/30/2026 1236002101
Recipient E.R. Squibb & Sons, L.L.C. $1,270.00 01/03/2025 Covered Recipient Physician A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors No dispute reported 06/30/2026 1236002111